Skip Navigation

This Article
Right arrow Full Text (PDF )
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Ferrari, C.
Right arrow Articles by Crosignani, P. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ferrari, C.
Right arrow Articles by Crosignani, P. G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 10, No. 7, pp. 1647-1652, 1995
© 1995 European Society of Human Reproduction and Embryology

research-article

Endocrinology: Cabergoline: a new drug for the treatment of hyperprolactinaemia

Carlo Ferrari, Gabriella Piscitelli and Pier Giorgio Crosignani1

Endocrine Unit, Fatebenefratelli Hospital; Pharmacia Farmitalia Carlo Erba Research and Development; First Department of Gynaecology and Obstetrics, University of Milan Milan, Italy

Correspondence: 1To whom correspondence should be addressed at: Clinica Obstetrica e ginecologia I, Facolta di Medicina a Chirurgia, Università degli Studi di Milano, Via Commenda 12, 20122 Milano, Italy

Recent clinical studies performed with the novel long-acting dopamine agonist cabergoline in the inhibition and suppression of puerperal lactation and in the treatment of hyperprolactinaemic disorders are reviewed. Inhibition of puerperal lactation is achieved with a single 1.0 mg oral administration of the drug, with better efficacy and tolerability results in comparison with bromocriptine, 2.5 mg twice daily for 14 days; 1.0 mg cabergoline (given as 0.25 mg twice daily for 2 days to minimize adverse events) is also effective and well tolerated for the suppression of established lactation. In the treatment of hyperprolactinaemic amenorrhoea, 1–2 mg weekly doses of cabergoline (given on a twice weekly schedule) compare favourably with 5–10 mg daily bromocriptine (given on a twice daily schedule) both for biochemical (normalization of serum prolactin concentrations) and clinical efficacy (resumption of ovulatory cycles) as well as for tolerability. The results of these double-blind, reference therapy-controlled studies have been confirmed by several open studies, that also showed tumour shrinkage in most patients with macropro-lactinomas and many patients with microprolactinomas. Persistence of normal or at least lower than pretreatment serum prolactin concentrations for several months after cabergoline withdrawal, together with persistence of cyclic ovulatory menses, has been also demonstrated. It is therefore suggested that cabergoline should become the drug of choice when inhibition or suppression of puerperal lactation is required and for the treatment of hyperprolactinaemic disorders.

Key words: amenorrhoea/cabergoline/hyperprolactinaemia/lactation


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.